You are here

  • Home
  • Archive
  • Volume 62, Issue 7
  • Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study

Article Text

Article menu
Download PDFPDF
Letter
Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study
  1. G Provenzano1,
  2. A Termini2,
  3. C Le Moli2,
  4. F Rinaldi2
  1. 1Department of Internal Medicine, Section of Autoimmune Diseases, A.O. “Villa Sofia – CTO”, Palermo, Italy
  2. 2Division of Internal Medicine II, A.O. “V Cervello”, Palermo, Italy
  1. Correspondence to:
    Dr G Provenzano, Via Massimo d’Azeglio No 2, 90143 Palermo, Italy;
    giuseppe.provenzano5{at}tin.it

https://doi.org/10.1136/ard.62.7.680

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Psoriatic arthritis (PsA) used to be considered a mild disease, but the development of erosive and deforming arthritis has been shown in a large proportion of patients.1

    Disease modifying antirheumatic drugs (DMARDs) often do not achieve a satisfactory control of articular symptoms and there is no evidence of their effect on the progression of joint damage.2 Tumour necrosis factor α (TNFα) has a role in the pathogenesis of PsA,3 and there are some encouraging reports about the efficacy of TNFα neutralising agents for the treatment of the spondyloarthropathies, including PsA.4–8

    METHODS AND RESULTS

    We evaluated in an open label, six month pilot study the safety and efficacy of infliximab in association with methotrexate (MTX) in 12 patients with PsA resistant to conventional DMARD treatment.

    Patients were considered eligible for the study if they fulfilled all of the following criteria: (a) diagnosis of psoriasis confirmed by a dermatologist; (b) diagnosis of spondyloarthropathy according to the European Spondyloarthropathy Study Group criteria9; (c) active disease …

    View Full Text